Lymphoma clinical trials

Clinical trials showed therapeutic efficacy in a broad spectrum of tumors these include SCLC, testicular tumors, sarcomas, breast cancer, renal cell cancer, pancreatic tumors and lymphomas. Ifosfamide is less myelosuppressive than cyclophosphamide but is more toxic to the bladder. Therefore it is recommended that ifosfamide is coadministered with the thiol compound mesna to avoid hemorrhagic cystitis and to reduce the risk of developing bladder cancer. Other side effects include neurotoxicity and myelosuppression. 

A large and rapidly growing number of clinical trials (phase I and phase II) evaluating the potential of DNA vaccines to treat and prevent a variety of human diseases are currently being performed ( http // clinicaltrials.gov) however, there is yet no licensed DNA vaccine product available for use in humans. The clinical trials include the treatment of various types of cancers (e.g., melanoma, breast, renal, lymphoma, prostate, and pancreas) and also the prevention and therapy of infectious diseases (e.g., HIV/ABDS, malaria, Hepatitis B vims, Influenza vims, and Dengue vims). So far, no principally adverse effects have been reported from these trials. The main challenge for the development of DNA vaccines for use in humans is to improve the rather weak potency. DNA vaccines are already commercially available for veterinary medicine for prevention of West Nile Vims infections in horses and Infectious Hematopoetic Necrosis Vims in Salmon. 

Therapeutic efficacy of adoptively transferred cytotoxic T lymphocytes (CTL) has been demonstrated in clinical trials for cytomegalovirns (CMV)-associated disease (Walter et al. 1995), for EBV-associated lymphoma (Rooney et al. 1995) and nasopharyngeal carcinoma (Comoli et al. 2005) as well as for chronically active EBV infection (Savoldo et al. 2002). 

Interferon does not only inhibit vims replicahon, it also has mulhple effects on cell metabolism and slows down the growth and mulhplicahon of treated cells. This is probably responsible for its widely reported anhtumour effect Encouraging results have been reported from clinical trials of interferon against several human tumours such as osteogenic sarcoma, myeloma, lymphoma and breast cancer. 

LL, a 47-year-old man, was diagnosed with high-risk diffuse large cell B-cell non-Hodgkin s lymphoma (NHL) 12 months ago. LL had a complete response to his initial treatment of six cycles of RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). LL is participating in a clinical trial and is randomized to receive a myeloablative autologous HCT TBI days 8 to 5, etoposide day 4, rest day 3, cyclophosphamide day 2, rest day 1, with infusion of autologous PBPC on day 0. 

Ga Ga(N03)3 Hypercalcemia of malignancy Ganite. Possible anticancer agent. In clinical trials for use in lymphomas... 

Van Oers, M.H., Hagenbeek, A., Van Glabbeke, M., and Teodorovic, L, Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin s lymphoma a phase III randomized clinical trial — Intergroup Collaborative Study, Ann. HematoL, 81, 553-557, 2002. 

HDAC inhibitors have received tremendous attention with the recent FDA approval of Vorinostat (Zolinza) or suberoylanilide hydroxamic acid (SAHA) for the treatment of cutaneous T-cell lymphoma (CTCL). Multiple compounds have thus entered into clinical trials for a wide variety of diseases. Many of these compounds were inspired in some part from HDAC natural product inhibitors. In addition, one natural product Romidepsin has also gained FDA approval for treating cutaneous T-cell lymphoma. 

Malignancies In the controlled portions of clinical trials of all the TNF-blocking agents, more cases of lymphoma have been observed among patients receiving the TNF blocker compared with control patients. 

B. Indications and use Rituxan is the first FDA-approved monoclonal antibody for the treatment of cancer. Several clinical trials have demonstrated efficacy of this chimeric antibody against NHL. Rituxan is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin s lymphoma (indolent lymphoma). 

---